| Oct 8 |
Sector Update: Health Care Stocks Rise Late Afternoon
|
| Oct 8 |
PTC Therapeutics sees positive long-term results on vatiquinone for Friedreich ataxia
|
| Oct 8 |
PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
|
| Oct 4 |
3 Top Stocks That Could Still Rocket Higher in 2024
|
| Oct 1 |
PTC Therapeutics brain disorder therapy granted FDA review
|
| Oct 1 |
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
|
| Oct 1 |
5 FDA decisions to watch in the fourth quarter
|
| Sep 26 |
PTC Therapeutics Huntington's disease candidate nabs FDA Fast Track status
|
| Sep 26 |
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
|
| Sep 12 |
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
